Gf Fund Management Co. Ltd. Larimar Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.62 Trillion
- Q4 2024
A detailed history of Gf Fund Management Co. Ltd. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,340 shares of LRMR stock, worth $4,274. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,340Holding current value
$4,274% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$67.7 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$20.6 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$19.3 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$14.8 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.2 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $138M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...